{"id":11308,"date":"2018-10-30T15:09:12","date_gmt":"2018-10-30T14:09:12","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=11308"},"modified":"2018-11-06T15:14:02","modified_gmt":"2018-11-06T14:14:02","slug":"fda-launches-action-plan-to-promote-biotech-innovation-in-plant-animal-and-human-health","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/fda-launches-action-plan-to-promote-biotech-innovation-in-plant-animal-and-human-health\/","title":{"rendered":"FDA launches action plan to promote biotech innovation in plant, animal and human health"},"content":{"rendered":"

Scientific advancements such as genome editing have led to the ability to more efficiently and precisely alter the genomes of plants and animals to produce desired traits. Genome editing in plants and animals has a broad range of potential applications in areas including food (for humans and animals), agriculture, and health.<\/p>\n

The U.S. Food and Drug Administration is pleased to share the\u00a0Plant and Animal Biotechnology Innovation Action Plan<\/a><\/strong><\/span>. This plan provides an overview of priorities the FDA will pursue to support innovation in plant and animal biotechnology and to advance the agency\u2019s public health mission.<\/p>\n

This Action Plan aims to implement and clarify risk-based policies with the goals of ensuring that developers know what they need to do to efficiently bring a product to market, and that consumers and the public understand how the FDA\u2019s regulatory system helps ensure the safety of such products. The Action Plan identifies concrete priorities in three key areas:<\/p>\n

    \n
  1. Advancing public health by promoting innovation<\/li>\n
  2. Strengthening public outreach and communication<\/li>\n
  3. Increasing engagement with domestic and international partners<\/li>\n<\/ol>\n

    Taken together, these priorities are intended to ensure the safety of plant and animal biotechnology products, foster continued public confidence in the FDA\u2019s regulation of these products, and avoid unnecessary barriers to future innovation consistent with the FDA\u2019s mission to protect and promote public health.<\/p>\n

    As a first step in the implementation of this Action Plan, FDA is announcing:<\/p>\n